CoChat

Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration

Open access

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Abstract

Current therapy to slow disease progression in patients with neovascular age-related macular degeneration (AMD) entails regular intravitreal anti-vascular endothelial growth factor (VEGF) injections, often indefinitely. Little is known about the burden imposed on patients by this repetitive treatment schedule and how this can be best managed. The aim of this study was to explore the psychosocial impact of repeated intravitreal injections on patients with neovascular AMD. Forty patients (16 males, 24 females) with neovascular AMD undergoing anti-VEGF treatment were recruited using purposive sampling from a private ophthalmology practice and public hospital in Melbourne. Patients were surveyed using the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ; Bradley, Health Psychology Research Unit, Surrey, England) and underwent semi-structured, one-on-one interviews. Interview topics were: treatment burden and satisfaction; tolerability; barriers to adherence; treatment motivation; and patient education. Interviews were audio recorded and thematic analysis performed using NVivo 10 (QSR International, Doncaster, Australia). Patients recognised the importance of treatment to preserve eyesight, yet experienced significant psychosocial and practical burden from the treatment schedule. Important issues included treatment-related anxiety, financial considerations and transport burden placed on relatives or carers. Many patients were restricted to sedentary activities post-injection owing to treatment side effects. Patients prioritised treatment, often sacrificing family, travel and social commitments owing to a fear of losing eyesight if treatment was not received. Whilst anti-VEGF injections represent the current mainstay of treatment for neovascular AMD, the ongoing treatment protocol imposes significant burden on patients. An understanding of the factors that contribute to the burden of treatment may help inform strategies to lessen its impact and assist patients to better manage the challenges of treatment.

Overview

Integrity signals

Registry

Crossref · 10.1080/13548506.2016.1274040

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Research works printed but not linked: 4

  1. Avci, R., Inan, S., Polat, O., Kusbeci, T., Yavas, G., & Dogan, M. (2013). Non-compliance to the intravitreal anti-VEGF injections in patients with exudative age-related macular degeneration. Paper presented at the ASRS 31st Annual Meeting, Toronto.
  2. 10.1111/ceo.2011.39.issue-2 · doi:10.1111/ceo.2011.39.issue-2
  3. Mitchell, J., Brose, L., & Bradley, C. (2007). Design of a measure of satisfaction with treatment for Macular Degeneration (MacTSQ). Paper presented at the International Society for Quality of Life Research Meeting, Canada.
  4. Regillo, C. (2014). Anti-VEGF maintenance therapy for neovascular AMD. Retina Today, 9, 63–67.

Cited by

See all 126

Metadata

Authors
Boyle, J., Vukicevic, M., Koklanis, K., Itsiopoulos, C., & Rees, G.
Affiliations
  • La Trobe University (AU)
  • Royal Children's Hospital (AU)
  • The University of Melbourne (AU)
Corresponding author
Boyle, Jessica
Venue
Psychology, Health & Medicine
Published
2017-01-09
Volume
23
Issue
2
Pages
127-140
ISSN
  • 1354-8506 (ISSN-L)
  • 1465-3966
OpenAlex
W2568773933
Cited by
119
References
28
Citations by year
2026: 14 · 2025: 15 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 28 · 2020: 13 · 2019: 7 · 2018: 4 · 2017: 3
FWCI
7.20
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Psychology Health & Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • RMIT Research Repository (RMIT University Library) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Victorian Branch
  • La Trobe University
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Keywords
neovascular age-related macular degeneration, anti-VEGF therapy, intravitreal injection, treatment burden, patient satisfaction, medication adherence, treatment-related anxiety, financial burden, caregiver burden, treatment side effects, patient education, treatment motivation, psychosocial impact
MeSH terms
Aged, Aged, 80 and over, Australia, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Wet Macular Degeneration, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1080/13548506.2016.1274040
The paper
Boyle, J., Vukicevic, M., Koklanis, K., Itsiopoulos, C., & Rees, G. (2018). Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychology, Health & Medicine. https://doi.org/10.1080/13548506.2016.1274040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.